+57.7%
HAL vs MRNA
-4.5%
+62.3%
-54.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.1% | -3.4% | +6.6% | +3.2% |
| 7D | +6.1% | -12.1% | +18.2% | +6.4% |
| 30D | +2.9% | -1.3% | +4.2% | +2.8% |
| 3M | +3.3% | +250.9% | -247.6% | -2.1% |
| 6M | -16.9% | +343.0% | -359.9% | -22.9% |
| YTD | +21.2% | +657.4% | -636.3% | +7.4% |
| 1Y | +27.5% | +794.9% | -767.4% | +11.5% |
| 3Y | -6.4% | +218.1% | -224.6% | -15.2% |
| All | +57.7% | -4.5% | +62.3% | +41.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling